Skip to main content

Thalomid & Revlimid

Related Lawyers: Brent W. Landau, Melinda R. Coolidge, Walter D. Kelley Jr., Katie R. Beran, Tamara Freilich
Related Practice Areas: Antitrust / Competition

In re Thalomid and Revlimid Antitrust Litig., No. 2:14-cv-06997-KSH-CLW (D.N.J.) – Hausfeld represents a class of plaintiffs, who allege that Celgene engaged in a multi-faceted scheme to maintain its monopoly and interfere with competitors’ efforts to enter the market with generic versions of Thalomid and Revlimid. Plaintiffs allege that Celgene acted to delay the onset of generic competition and charged users billions of dollars for these products.

On July 24, 2019, the parties announced that they had reached a settlement agreement on behalf of all persons or entities who purchased and/or paid for some or all of the purchase price of Thalomid or Revlimid in any form, before the Preliminary Approval Date, in California, the District of Columbia, Florida, Kansas, Maine, Massachusetts, Michigan, Nebraska, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, or Tennessee, for consumption by themselves, their families, or their members, employees, insureds, participants, or beneficiaries.

Celgene has agreed to pay $55 million to settle these claims. 

Supporting Documents